Auris Medical

$0.9899
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.0339 (+3.55%) As of 2:57 PM UTC today

Why Robinhood?

You can buy or sell Auris Medical and other stocks, options, and ETFs commission-free!

About EARS

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in 2003 and is headquartered in Hamilton, Bermuda. The listed name for EARS is Auris Medical Holding Ltd. Common Shares 0.01 SF (Bermuda).

CEO
Thomas Meyer
Employees
12
Headquarters
Hamilton, Hamilton
Founded
2003
Market Cap
4.45M
Price-Earnings Ratio
Dividend Yield
Average Volume
342.70K
High Today
$0.99
Low Today
$0.9587
Open Price
$0.9587
Volume
85.07K
52 Week High
$1.83
52 Week Low
$0.65

Collections

EARS Earnings

-$0.12
-$0.08
-$0.04
$0.00
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
Expected Mar 16, Pre-Market

You May Also Like